[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine-disorders":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,62,83,115,153,175,199,228,258,280,310,334,370,403,427,458,480,507,536,561,584,605,629,655,678],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":25,"studyType":26,"phases":4,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100551403","migraine-attack-pain-phase-prediction-study-100551403",false,"NCT06459635","Migraine Attack Pain Phase Prediction Study","Prediction Study of the Pain Phase of Migraine Attacks in Patients With Episodic Migraine","PREDI-CRISIS","Inclusion Criteria:\n\n* Age between 15 years and 69 years.\n* Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.\n* History of migraine of at least 1 year of evolution.\n* Normal neurological examination.\n* Have given your informed consent.\n* Be able to describe your clinical situation and the characteristics of your headache.\n* Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).\n* User-level management capacity of \"smartphone\" type electronic devices.\n* Be able to complete two months of study follow-up.\n\nExclusion Criteria:\n\n* Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.\n* Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.\n* Neurological focus in the examination.\n* Pregnancy or breastfeeding period.\n* Patients with known heart disease or bronchopathy, Sjögren\\'s syndrome, diabetes mellitus, or hypo\u002Fhyperthyroidism.\n* Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.\n* Anatomical problem that makes the use of the device impossible.\n* Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.",true,"ALL","18 Years","65 Years",{"count":23,"type":24},70,"ESTIMATED","2 Months","OBSERVATIONAL","The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.",[29,30,31,32,33],"Migraine","Migraine Headache","Migraine Disorders","Migraine Without Aura","Migraine With Aura",[29,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"Headache","Predict","Prediction","headache prediction","predict headache","migraine prediction","predict migraine","migraine attacks","migraine attack","headache attack","migraine attack prediction","predict migraine attack","prediction algorithm","algorithm","RECRUITING","2026-06-30",{"date":52,"type":53},"2026-07-02","ACTUAL",{"date":55,"type":53},"2023-10-09",{"date":57,"type":24},"2026-07",{"name":59,"class":60},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","OTHER",1,{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":26,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":61},"100465574","specified-drug-use-survey-on-ajovy-subcutaneous-injection-for-long-term-use-100465574","NCT05342493","Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use","AJOVY Subcutaneous Injection Long-term Specified Use-results Survey","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* patients with a known hypersensitivity to components of AJOVY",{"count":70,"type":24},1000,"To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.",[31],"2026-06-17",{"date":75,"type":53},"2026-06-22",{"date":77,"type":53},"2022-04-20",{"date":79,"type":24},"2029-06-22",{"name":81,"class":82},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":91,"enrollmentInfo":92,"targetDuration":94,"studyType":26,"phases":4,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":61},"100641202","embrace-obs-single-site-observational-registry-of-patient-reported-outcomes-following-mma-embolization-for-migraine-100641202","NCT07652034","EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine","Enduring Migraine Benefit From Responsive Artery Coil Embolization - Observational (EMBRACE-OBS): A Single-Site Registry of Patient-Reported Outcomes Following Routine Clinical Care for Migraine","EMBRACE-OBS","Inclusion Criteria:\n\n* Adults aged 18 to 64 years\n* Diagnosis of migraine\n* Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation\n* Able and willing to provide informed consent\n* Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy at the time of enrollment\n* Inability to provide informed consent\n* Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n* Insufficient clinical or patient-reported outcome data for the planned analyses","64 Years",{"count":93,"type":24},50,"12 Months","EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.",[31,97,29],"Chronic Migraine Headache",[99,100,29,35,101,102,103,104,89],"Middle Meningeal Artery Embolization","MMA Embolization","Patient-Reported Outcomes","HIT-6","Observational Registry","Neurointervention","NOT_YET_RECRUITING","2026-06-16",{"date":108,"type":53},"2026-06-18",{"date":110,"type":24},"2026-07-01",{"date":112,"type":24},"2028-06-01",{"name":114,"class":82},"Cortex Neurovascular",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":19,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100417438","mind-body-balance-for-pediatric-migraine-100417438","NCT04715685","Mind Body Balance for Pediatric Migraine","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders(ICHD) criteria\n* Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 4 and ≤ 28.\n* PedMIDAS: PedMIDAS Disability Score \\> 4, indicating at least mild disruption in daily activities and \\\u003C 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Use of one or more of the following prescribed nutraceuticals and\u002For preventive anti-migraine medications at the time or randomization or be on a stable dose of one or more of the following throughout the 12 weeks of the study \\[Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol\u002FCholecalciferol), Depakote (Divalproate), Inderal (Propanerol), Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)\\]\n* Language: English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Continuous migraine defined as unrelenting headache for a 28 day period\n* Must agree not to take non-specific acute medication, such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month (to prevent medication overuse headache)\n* PedMIDAS Disability Score \\> 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)\n* Present severe psychiatric disease, alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) or other circumstances, that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study","10 Years","17 Years",{"count":124,"type":24},260,"INTERVENTIONAL",[127],"NA","This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.",[35,130,131,29,31,33,32,132],"Headache Disorders","Headache, Migraine","Chronic Migraine",[134,135,136,137,138,139,140,141,142,143],"headache","migraine","cognitive behavioral therapy","pediatrics","mind body intervention","diaphragmatic breathing","progressive muscle relaxation","imagery","relaxation","biofeedback","2026-06-14",{"date":106,"type":53},{"date":147,"type":53},"2021-03-09",{"date":149,"type":24},"2026-11-30",{"name":151,"class":60},"Children's Hospital Medical Center, Cincinnati",2,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":161,"targetDuration":4,"studyType":125,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100572635","mma-embolization-for-refractory-chronic-migraine-100572635","NCT06735833","MMA Embolization for Refractory Chronic Migraine","Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine","MIGRAINE","Participant Inclusion Criteria, Candidates for this study must meet ALL the following inclusion criteria:\n\n1. Patient is between 18 and 65 years of age (inclusive) at the time of consent\n2. Age of onset of Chronic Migraine \\\u003C= 64 years\n3. Age of onset of migraine diagnosis \\\u003C 50 years\n4. Patient has a current diagnosis of refractory migraine\n5. Patient has a current diagnosis of Chronic migraine\n\nParticipant Exclusion Criteria, Candidates will be excluded from participation if ANY of the following apply:\n\n1. Patients with a history for the last 2 years of other primary headache types, or secondary headache types except medication overuse headache\n2. Patients with diagnosis of hemiplegic migraine or migrainous infarct\n3. Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc\n4. Women who are pregnant, lactating, or who are of childbearing age\n5. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Participants in observational, natural history, and\u002For epidemiological studies not involving intervention are eligible. Sponsor approval is required",{"count":23,"type":24},[127],"This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.",[31],"2026-06-05",{"date":167,"type":53},"2026-06-08",{"date":169,"type":53},"2025-04-23",{"date":171,"type":24},"2029-07-31",{"name":173,"class":82},"Cerenovus, Part of DePuy Synthes Products, Inc.",9,{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":125,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":61},"100471142","determining-the-utility-of-a-behavioral-intervention-in-chronic-migraine-100471142","NCT05415020","Determining the Utility of a Behavioral Intervention in Chronic Migraine","Feasibility, Acceptability, and Pilot Testing of a Behavioral Intervention for Chronic Migraine","RLB","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* other headache disorders including secondary headache disorders\n* children younger than 18 years old\n* current pregnancy",{"count":184,"type":24},60,[127],"This proposal will involve a pilot study to evaluate the feasibility, acceptability, and outcomes of a lifestyle behavior protocol in managing chronic migraine. Additionally, the proposal will investigate biomolecules that are uniquely involved in chronic migraine patients who respond to the protocol. Successful completion of this proposal will inform the design of a future full-scale behavioral clinical trial to control chronic migraine.",[29,35,31,132,188,130],"Lifestyle Factors",[31,35,190],"Lifestyle","2026-06-04",{"date":167,"type":53},{"date":194,"type":53},"2022-06-29",{"date":196,"type":24},"2027-07-31",{"name":198,"class":60},"Mayo Clinic",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":125,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100638204","using-virtual-reality-to-teach-mindfulness-to-people-with-migraine-100638204","NCT07599228","Using Virtual Reality to Teach Mindfulness to People With Migraine","Migraine Intervention Using Reality-Assisted Guided Experience","MIRAGE","Inclusion Criteria:\n\n* Adults aged 18-80\n* Diagnosed with episodic migraine and experience 4-10 migraine days\u002Fmonth\n* On a stable dose of CGRP mAb for three months prior\n* Satisfy 4 week run-in of 4-10 headaches\u002Fmonth\n* Not taking other preventive medications\n* Not pregnant, breastfeeding, or planning to become pregnant within study timeframe\n* Able and willing to use VR device\n* No history of significant psychiatric illness\n* Willing to comply with study procedures\n* English-speaking\n\nExclusion Criteria:\n\n* Medication overuse (\\>10 days\u002Fmonth)\n* Vertigo\u002Fvestibular dysfunction\n* Active psychiatric or neurological comorbidities\n* Pregnancy, breastfeeding or planning pregnancy within study timeframe\n* Significant visual\u002Fhearing\u002Fmobility impairment affecting VR use","80 Years",{"count":209,"type":24},160,[127],"The aim of this clinical trial is to learn if people with migraine can learn a type of biobehavioral therapy called Acceptance and Commitment Therapy (ACT) by using a virtual reality headset. Researchers are studying if this type of mindfulness therapy helps to decrease migraine-related disability. Participants will be randomized to treatment as usual or active virtual reality groups for four weeks. Everyone will keep symptom diaries, complete surveys, attend two clinic visits, and have two blood draws.",[31,33,32,213],"Episodic Migraine",[215,135,216,217,218],"acceptance and commitment therapy (ACT)","virtual reality","mindfulness","Calcitonin Gene-Related Peptide monoclonal antibody therapy","2026-05-14",{"date":221,"type":53},"2026-05-20",{"date":57,"type":24},{"date":224,"type":24},"2031-01",{"name":226,"class":60},"Brigham and Women's Hospital",3,{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":207,"enrollmentInfo":235,"targetDuration":4,"studyType":125,"phases":237,"briefSummary":238,"conditions":239,"keywords":242,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":227},"100636654","greater-occipital-nerve-block-for-migraine-with-medication-overuse-headache-100636654","NCT07568496","Greater Occipital Nerve Block for Migraine With Medication Overuse Headache","GONB_MOH","Inclusion Criteria:\n\n* Patients who have a diagnosis of migraine with medication overuse headache according to ICHD-3 criteria confirmed by a neurologist\n* Female patients will be screened for pregnancy planning and married female patients must undergo a urine pregnancy test\n\nExclusion Criteria:\n\n* Patients who have other types of headache disorders other than migraine\n* Patients who have a previous history of allergy to corticosteroid or lidocaine\n* Patients who had previous skull surgery\n* Pregnant women\n* Patients with a history of uncontrolled depression, or psychosis\n* Patients who get or plan to get CGRP-targeted therapies or botulinum toxin injection\n* Patients with an increased risk of bleeding or underlying bleeding disorders",{"count":236,"type":24},130,[127],"Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH). Treatment of MOH is challenging and the primary therapeutic approach is reducing painkillers which helps decrease the number of headache days. As a part of the detoxification process to discontinue acute medications, bridging therapy is often needed to reduce withdrawal headache. Currently, there are data supporting the use of greater occipital nerve block as a preventive treatment in chronic migraine, but no placebo-controlled trial has evaluated the efficacy of greater occipital nerve block in MOH. Therefore, this research aims to demonstrate the efficacy of greater occipital nerve block in detoxification of migraine patients with MOH. Patients will be recruited from Headache Clinic at 3 centers in Thailand from February 2026 to January 2028. After recruitment, patients will be randomized into 2 groups at a 1:1 ratio using a block of four, namely group A and B. A 5-mL syringe of 2 mL of lidocaine 2% and 2 mL of methylprednisolone 40 mg\u002FmL (80 mg) will be prepared for each patient in group while a 5-mL syringe of 4 mL normal saline will be prepared for each patient in group B. Monthly headache days, duration, severity, acute medication type and number of usage days and relative headache status according to a 5-point Likert scale will be investigated at the 2 weeks, 1st, 2nd and 3rd month, MIDAS at the end of 3rd month.",[31,240,241],"Medication Overuse Headache","Greater Occipital Nerve Block",[243,244,245,246,247,248],"GONB","Nerve Block","Detoxification","MOH","Methylprednisolone","Lidocaine","2026-05-11",{"date":251,"type":53},"2026-05-13",{"date":253,"type":24},"2026-05-01",{"date":255,"type":24},"2028-11-01",{"name":257,"class":60},"Mahidol University",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":19,"minAge":121,"maxAge":122,"enrollmentInfo":265,"targetDuration":4,"studyType":125,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},"100507610","responding-with-evidence-and-access-for-childhood-headaches-100507610","NCT05889624","Responding With Evidence and Access for Childhood Headaches","Cognitive Behavioral Therapy Via Telehealth + Amitriptyline Compared to Cognitive Behavioral Therapy Via Telehealth: Pediatric Migraine Prevention (Responding With Evidence and Access for Childhood Headaches)","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura that meets the International Classification of Headache Disorders (ICHD) criteria 5 or presentation of continuous headache that includes migranous episodes based upon headache history obtained by site PI or designee. (includes presentation with or without medication overuse headache as well)\n* Headache Frequency: 4 or more headache days based upon prospective headache diary of 28 days prior to randomization\n* Amitriptyline Eligible: Site PI or medical staff determined participant to be eligible for clinical prescription of amitriptyline as a preventive treatment for migraine\n* English fluency: Able to complete the study visits and questionnaires in English\n\nExclusion Criteria:\n\n* Current treatment includes amitriptyline and\u002For CBT specific to headache care\n* Current prescribed preventive antimigraine medication within a period equivalent to \\\u003C 5 half-lives of that medication before entering the baseline phase\n* Current treatment with onabotulinumtoxinA (Botox) or CGRP-based monoclonal antibody medications for migraine prevention\n* Youth who are pregnant\n* Report of current or ongoing suicidal thoughts. Suicide attempt within the past six months. History of bipolar disorder, prolonged QT, or pre-existing significant constipation or gastroparesis\n* Any and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the participant",{"count":266,"type":24},400,[127],"This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will be compared to CBT via telehealth alone.",[35,130,131,29,31,33,32,132],[134,135,136,137,139,140,141,142,143],"2026-03-04",{"date":273,"type":53},"2026-03-06",{"date":275,"type":53},"2023-08-22",{"date":277,"type":24},"2027-12-31",{"name":151,"class":60},15,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":125,"phases":290,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":61},"100617067","embrace-study-enduring-migraine-benefit-from-responsive-artery-coil-embolization-100617067","NCT07313800","EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization","Enduring Migraine Benefit From Responsive Artery Coil Embolization (EMBRACE): A Single-Site, Non-Significant Risk Pilot Study of Middle Meningeal Artery Embolization Using FDA-Cleared Coils for Refractory Episodic Migraine","EMBRACE","Inclusion Criteria:\n\n* Age 18-60 years\n* Diagnosis of migraine (with or without aura)\n\n  -≥8 headache days per month\n* Failure of ≥2 preventive medication classes\n* Ability to complete electronic headache diary and surveys\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Secondary headache disorders\n* Prior MMA embolization\n* Contraindication to angiography or embolization\n* Pregnancy\n* Inability to comply with follow-up","60 Years",{"count":7,"type":24},[127],"This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).",[31,293,132],"Refractory Migraine",[99,100,293,295,296,297,298,299,300,301],"Coil Embolization","Neurovascular Intervention","Migraine Prevention","TEMMA","TEMMA procedure","TEMMA protocol","Targeted Embolization for Migraine Management","2026-02-02",{"date":304,"type":53},"2026-02-04",{"date":306,"type":24},"2026-03-01",{"date":308,"type":24},"2028-03-01",{"name":114,"class":82},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":288,"enrollmentInfo":317,"targetDuration":4,"studyType":125,"phases":319,"briefSummary":320,"conditions":321,"keywords":324,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":331,"leadSponsor":332,"locationsCount":152},"100606025","effects-of-pfo-closure-on-glymphatic-function-and-clinical-symptoms-in-patients-with-migraine-100606025","NCT07170176","Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine","The Impact of Percutaneous Patent Foramen Ovale Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine","Inclusion Criteria:\n\n1. Adults aged 18 to 60 years.\n2. Diagnosed with patent foramen ovale (PFO) with significant right-to-left shunt.\n3. For the case group: Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders (ICHD-3).\n4. For the control group: No history of migraine.\n5. Willing and able to provide written informed consent.\n6. Education level of primary school or higher.\n\nExclusion Criteria:\n\n1. Patients with a history of PFO closure or other migraine-related surgical treatments;\n2. Patients with other severe cardiac or neurological diseases, mental disorders, or psychological conditions;\n3. Patients with contraindications to closure surgery or MRI scans (e.g., severe infection, coagulation dysfunction, cardiac pacemakers, aneurysm clips, metallic foreign bodies in the eye, non-removable metal dentures, etc.);\n4. Patients unable to complete migraine symptom assessments or imaging examinations due to other reasons.",{"count":318,"type":24},150,[127],"Patent Foramen Ovale (PFO) is a common congenital heart defect. Recent studies have suggested a potential association between PFO and migraines, particularly migraine with aura. It is hypothesized that PFO may allow microemboli or vasoactive substances from venous blood to bypass pulmonary metabolism and enter the arterial system directly, potentially triggering migraines. Although PFO closure has been shown to reduce the frequency and severity of migraine attacks, its long-term efficacy and underlying mechanisms require further investigation.\n\nThis study aims to explore the characteristics of glymphatic system function in PFO patients and its relationship with migraine symptoms, as well as the impact of PFO closure on glymphatic function and its role in alleviating migraine symptoms. A case-control and self-controlled before-after study design is adopted. Two groups of participants are enrolled: a case group consisting of PFO patients with significant right-to-left shunt and migraine, and a control group comprising PFO patients with significant shunt but without migraine. According to clinical guidelines and after obtaining informed consent, eligible patients in the case group undergo percutaneous PFO closure.\n\nBy comparing migraine symptoms and glymphatic function indicators both before and after the procedure between the two groups, the interventional effect of PFO closure and its potential mechanism will be investigated. The primary endpoint is the improvement in migraine symptoms, while the secondary endpoints include glymphatic function metrics. The findings of this study will provide new theoretical insights and clinical guidance for the management of PFO-related migraines.",[31,322,323],"Patent Foramen Ovale","Right-to-Left Shunt, Cardiac",[322,29,325,326],"Glymphatic System","PFO Closure","2026-01-14",{"date":329,"type":53},"2026-01-16",{"date":327,"type":53},{"date":277,"type":24},{"name":333,"class":60},"First Affiliated Hospital Xi'an Jiaotong University",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":341,"targetDuration":4,"studyType":125,"phases":343,"briefSummary":344,"conditions":345,"keywords":361,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":61},"100619143","amylin-induced-migraine-attacks-without-aura-100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":342,"type":24},21,[127],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[346,130,347,348,349,350,351,352,31,35,353,354,355,356,357,358,359,360],"Headache Disorders, Primary","Brain Diseases","Nervous System Diseases","Central Nervous System Diseases","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Pain","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[29,35,353,359],"2026-01-05",{"date":327,"type":53},{"date":365,"type":24},"2026-02",{"date":367,"type":24},"2028-10-30",{"name":369,"class":60},"Danish Headache Center",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":18,"sex":378,"minAge":20,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":125,"phases":382,"briefSummary":383,"conditions":384,"keywords":391,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":61},"100548847","the-role-of-cytokines-and-regulatory-t-lymphocytes-in-migraine-pathophysiology-100548847","NCT06426316","The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.","Immune System, Inflammation, Migraine - The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology","SIIM","Inclusion Criteria:\n\n* female\n* 18 - 50 years of age\n* at least 50 kg\n* autoimmune\u002Finflammatory disease groups : with a diagnosis of multiple sclerosis, systemic lupus erythematous, rheumatoid arthritis, Crohn's disease, type 1 diabetes or endometriosis\n* migraine group : with a diagnosis of migraine with at least 4 headache days per month\n\nExclusion Criteria:\n\n* BMI \\\u003C or = 17 ou \\> or = 30kg\u002Fm²\n* type 2 diabetes, immune deficit, other chronic autoimmune or inflammatory disease\n* non-migraine headache, except for tension type headache of less than 4 days\u002Fmonth\n* pregnancy, delivery, miscarriage, breast-feeding, participation in a medically assisted human reproduction program (ovary stimulation\u002Fhormone therapy) \\\u003C 3 months before blood sampling\n* Menopause, hysterectomy, or bilateral oophorectomy\n* Hormone therapy (besides contraception and treatment of endometriosis)\n* bone marrow or solid organ transplant\n* guardianship, curatorship, safeguard of justice or deprivation of liberty\n* for patients : diagnosis of several autoimmune or inflammatory diseases\n* for controls : diagnosis of an autoimmune or inflammatory disease\n* for non-migraine participants : migraine","FEMALE","50 Years",{"count":381,"type":24},396,[127],"Migraine is a frequent and debilitating neurologic disorder. It is more frequent in women, and more prevalent in patients with autoimmune and\u002For inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn's disease (CD), systemic lupus erythematosus (SLE) and endometriosis, whereas patients with long standing type 1 diabetes mellitus (T1DM) - an autoimmune but non inflammatory disease - seem to be less affected compared to the general population. Despite new migraine prevention treatments, a large number of patients remain unresponsive to currently available anti-migraine therapy and migraine pathophysiology remains unclear. Several peptides (calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase activating peptide-38 (PACAP-38), vasoactive intestinal polypeptide (VIP)) and hormones (estrogens, prolactin) and the immune system play an important role in migraine pathophysiology. Among T lymphocytes, regulatory T (Treg) cells suppress inflammation. Studies have evidenced higher levels of inflammatory molecules (cytokines) in migraine patients and have suggested decreased proportions of Treg cells in migraine, as well as in MS, RA, CD and SLE, whereas inflammation declines and Treg levels seem increased in long-standing T1DM. Inflammation, which participates in migraine pain, seems to be a common factor for migraine and these diseases. However, these studies display conflicting results and further investigation is required to better understand the mechanisms behind migraine.\n\nIn this study, the investigators will compare Treg levels, as well as identify Treg subpopulations and measure cytokine levels in migraine and migraine-free participants with and without an autoimmune\u002Finflammatory disorder (MS, RA, CD, SLE, T1DM and endometriosis).",[31,353,385,386,387,388,389,390],"Autoimmune Diseases","Multiple Sclerosis","Endometriosis","Rheumatoid Arthritis","Crohn Disease","Lupus Erythematosus",[31,353,392,393],"Cytokines","Regulatory T cell","2025-11-17",{"date":396,"type":53},"2025-11-20",{"date":398,"type":53},"2025-06-02",{"date":400,"type":24},"2027-04-30",{"name":402,"class":60},"University Hospital, Clermont-Ferrand",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":411,"targetDuration":413,"studyType":26,"phases":4,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":61},"100605507","italian-migraine-registry-i-graine-new-100605507","NCT07163416","(Italian Migraine Registry, I-GRAINE-NEW)","Project for the Construction of the Italian Migraine Registry I-GRAINE-New","I-GRAINE-NEW","Inclusion Criteria:\n\n* Adult Patients(Age ≥ 18 years) of both sexes\n* Diagnosis confirmed of episodic migraine ( \\\u003C15 days\u002Fmonth ) with or without aura or chronic migraine (\\>15days\u002Fmonth) ,with or without headeche due to overuse of analgesics;\n* Provision of signed and dated the Informed Consent Form before the inclusion in the study\n\nExclusion Criteria:\n\n* Patients affected by other forms of primary or secondary headaches or in whom the diagnosis is not certain",{"count":412,"type":24},2030,"5 Years","Rationale Understanding the mechanisms and evolution of migraine is hampered by its nature as a chronic \"evolutionary\" condition. Patients often come to migraine centers after years of disabling disease, non-specific diagnoses and ineffective treatments. When patients are admitted to the center is therefore the time when their history in terms of disease evolution and healthcare costs is most effectively collected, but also when it is assumed that the treatment strategy offered to the patient will have a greater impact.\n\nFor this reason, it was decided to conduct a large-scale retrospective and prospective observational study in order to draw a detailed picture of the situation of patients not followed by a specialized center and of the natural history of the disease once the pathway at the specialized center has started.\n\nDesign A multicenter, observational, retrospective and prospective cohort study, aimed at obtaining a more detailed picture of the situation of patients not followed by a specialized center and of the natural history of the disease once the pathway at the specialized center has started.6,000 of the incident patients (defined as those who had their first visit during the 6 months preceding enrollment in the registry), will be invited to take part in a follow-up and expanded data collection study.\n\nPatients will be consecutively enrolled by specialists at each individual site.. Eligible patients who agree to take part in the study by signing an informed consent form will be assessed clinically and through a direct interview with a structured questionnaire organized in several ad hoc sections.\n\nObjectives: The aim of the study is:\n\nanalyze episodic and chronic migraine in Italy from an epidemiological point of view, especially in terms of prevalence of the two forms of migraine and their endophenotypes in different population subgroups; 2. characterize the demographic distribution and clinical characteristics of patients (including the definition of endophenotypes); 3. measure the influence of the disease on the patient's daily activity, in terms of disability (assessed using the validated MIDAS and HIT-6 scales); 4. study the clinical and care pathway (patient journey) and identify the preferred care pathways based on the characteristics of the patients and the migraine subtype; 5. evaluate the prescribed pharmacological treatments, medical visits and diagnostic procedures performed (ascertaining the degree of adherence to current guidelines); 6. analyze the use of health resources by migraine patients, with particular attention to their impact on the SNS.\n\nVisits and Treatments:\n\nBaseline Visit: Patients enrolled in the study will undergo a thorough clinical and neurological examination.\n\nFollow-up Visits: Clinical data will continue to be collected over time, at each scheduled clinic visit based on the needs of clinical practice.\n\nStudy Population: Adult patients of both sexes with episodic or chronic migraine who have recently attended a specialized migraine center in the I-GRAINE-NEW registry.\n\nEstimated Study Duration: The duration of each patient's participation in the study is 24 months from the date of the initial visit to the participating migraine site",[31],[417],"Migraine,Register,Italy","2025-09-01",{"date":420,"type":53},"2025-09-09",{"date":422,"type":53},"2021-04-19",{"date":424,"type":24},"2026-03-05",{"name":426,"class":60},"IRCCS San Raffaele Roma",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":125,"phases":436,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":61},"100600103","phase-4-evaluation-of-efficacy-and-safety-of-topical-cannabidiol-canvert-m-produced-by-alasht-pharmed-co-iran-in-the-treatment-of-migraine-attacks-100600103","NCT07093138","Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks","Inclusion criteria:\n\n1. Males and females with age of 18 to 55 years\n2. Age of migraine onset ˂ 50 years\n3. Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year\n4. Having a history of 2-8 attacks per month\n5. Remaining stable on prophylactic medication (if used) during the 2 months prior to screening and throughout the study period\n6. Using effective contraception by the women of childbearing potential during the study\n7. Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments\n\nExclusion criteria:\n\n1. Having a diagnosis of other primary (cluster and tension) and secondary headache disorders\n2. Having a history of chronic migraine headache\n3. History of resistant or refractory migraine headaches based on European Headache Federation consensus\n4. Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M\n5. History of psychiatric and neurologic disorders (except migraine) or any medical comorbid conditions that interfere with the study results\n6. History of nasal sensitivity or allergy to menthol, lavender, rosemary, eucalyptus, wintergreen and basil oil\n7. The presence of any skin lesions in the areas where the product is used\n8. Treatment with any investigational agent within 30 days prior to screening\n9. History of substance use disorders\n10. Nursing mothers, pregnant women, and women who plan to become pregnant during the study period\n11. Taking carbamazepine, cilostazol, citalopram, clarithromycin, clobazam, colchicine, cyclosporine, digoxin, itraconazole, phenobarbital, phenytoin, rifampin, sirolimus, tacrolimus, tizanidine, and warfarin within 14 days of the study procedure","55 Years",{"count":435,"type":24},30,[437],"PHASE4","Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. This phase IV, single-arm, open-label clinical trial evaluated the efficacy and safety of Canvert-M in males and females aged 18 to 55 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), for the treatment of migraine attacks.\n\nThe primary objective was to assess the reduction in headache intensity using a 4-point scale (0=no headache, 1=mild headache, 2=moderate headache, 3=severe headache).\n\nSecondary objectives included evaluating additional efficacy and safety outcomes of Canvert-M in managing migraine attacks.",[31],[441,442,443,444,445,446,447,448,35],"Cannabidiol","Migraine disorders","Mentha piperita","Lavandula","Eucalyptus","Ocimum basilicum","Rosmarinus","Gaultheria","2025-07-29",{"date":451,"type":53},"2025-07-30",{"date":453,"type":53},"2025-07-16",{"date":455,"type":24},"2025-09-16",{"name":457,"class":82},"Alasht Pharmed",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":288,"enrollmentInfo":466,"targetDuration":4,"studyType":125,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":227},"100563978","treatment-of-episodic-migraine-with-auricular-neuromodulation-100563978","NCT06623188","Treatment of Episodic Migraine With AURICular Neuromodulation","Treatment of Episodic Migraine With AURICular Neuromodulation: a Prospective Randomized, Placebo-controlled Study","MENAURIC","Inclusion Criteria:\n\n* 18 years ≥ Aged ≤ 60 years\n* Moderate to severe Migraine for at least one year\n* Migraines appeared before the age of 50 and diagnosed according to IHS (international headache society) criteria.\n* Therapeutic failure of at least 2 migraine preventive medications\n* Frequency of migraine days ≥ 4 per month and \\\u003C 15 per month\n\nExclusion Criteria:\n\n* Pathology of the auricle (e.g. epithelioma)\n* Patient treated with botulinum toxin for migraine ≤ 2 months\n* Patient treated with anti-cgrp for migraine, with last injection less than 3 months ago\n* Patient treated with non-invasive auricular stimulation ( TENS)",{"count":467,"type":24},106,[127],"Migraine is a ubiquitous pathology affecting approximately 1 billion individuals and being the leading cause of morbidity worldwide before the age of 50. Migraine treatment consists of two main approaches: acute treatment to relieve headache symptoms and preventive treatment to reduce the frequency of migraine attacks by at least 50%. Preventive treatment involves medications such as beta-blockers, antiepileptics, calcium channel blockers, and a new therapeutic class called calcitonin gene-related peptide (CGRP) inhibitors. While traditional treatments have modest efficacy and limited tolerability, CGRP inhibitors have shown better tolerability and superior efficacy. However, their prescription in France is restricted to neurologists and specialized pain evaluation and treatment units. Additionally, the long-term effects of CGRP inhibition on blood pressure control and vascular homeostasis are not fully understood.\n\nIn addition to pharmacological preventive treatment, non-pharmacological approaches have emerged, such as auricular neurostimulation. This can be achieved through electrical stimulation of the cymba conchae, considered a non-invasive alternative to invasive vagal stimulation, and has shown benefits in reducing the number of migraine days compared to a placebo. Another approach involves stimulation of specific areas of the entire auricle using techniques borrowed from auriculotherapy (auricular acupuncture).\n\nThe objective of the study is to demonstrate that auricular neuromodulation, performed with a laser device, targeted and personalized on selected areas of the auricle, has a beneficial effect on the number of moderate to severe migraine days per month.",[31],"2025-06-27",{"date":473,"type":53},"2025-07-01",{"date":475,"type":53},"2025-05-20",{"date":477,"type":24},"2027-11-20",{"name":479,"class":60},"Hôpital Européen Marseille",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":487,"targetDuration":4,"studyType":125,"phases":489,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":61},"100374131","phase-3-idebenone-for-the-preventive-treatment-of-migraine-100374131","NCT04151472","Idebenone for the Preventive Treatment of Migraine","A Randomized, Double-blinded, Placebo-controlled Trial of Idebenone in the Prevention of Episodic Migraine","Inclusion Criteria:\n\n1. Clinical diagnosis of episodic migraine.\n2. Patients (18-65 years) were eligible if they met International Headache Society (IHS) criteria for episodic migraine with\u002F without aura with a migraine history 1 year\n3. Two to eight attacks per month, 5 days\u002Fmonth of interval headaches.\n4. No over consumption of acute anti-migraine medication.\n5. No other prophylactic medication (washout 3 months).\n6. No serious organic or psychiatric disease.\n7. Only women with contraceptive protection.\n\nExclusion Criteria:\n\n1. Clinical diagnosis of chronic migraine.\n2. Subjects previously discontinued idebenone due to adverse events.\n3. Subjects are taking idebenone or had taken idebenone within 14 days prior to enrollment.\n4. Subjects with continuous headaches.",{"count":488,"type":24},180,[490],"PHASE3","Idebenone improves energy metabolism similarly to Coenzyme Q10, which is effective in migraine prophylaxis. The investigators compare idebenone (90 mg\u002Fday, 270 mg\u002Fday) and placebo in 180 migraine patients in a double-blind, randomized, placebo-controlled, multicenter trial to study whether Idebenone is superior to placebo in the prevention of episodic migraine with or without aura.",[31,130],[494,495,496,497],"Migraine Prophylaxis","Mitochondrial Dysfunction","Idebenone","Individualized Treatment","2025-05-12",{"date":500,"type":53},"2025-05-15",{"date":502,"type":53},"2021-12-08",{"date":504,"type":24},"2025-12-31",{"name":506,"class":60},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":286,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":514,"enrollmentInfo":515,"targetDuration":517,"studyType":26,"phases":4,"briefSummary":518,"conditions":519,"keywords":520,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":61},"100483062","eptinezumab-in-real-world-evidence-multicenter-real-life-cohort-study-in-migraine-100483062","NCT05570149","EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.","EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)","KEY INCLUSION CRITERIA\n\n1. Age between 18 and 75 years;\n2. Males and females;\n3. Willingness to sign the informed consent;\n4. High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;\n5. Chronic migraine, according to the ICHD-III criteria;\n\nKEY EXCLUSION CRITERIA\n\n1. Other headaches different than migraine;\n2. Known intolerance to eptinezumab or eccipients;\n3. Current treatment with other mAbs;\n4. Vascular disease or Raynaud.","75 Years",{"count":516,"type":24},500,"3 Years","The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.",[31],[521,522,523,524,525,526,527],"Eptinezumab,","Calcitonin gene-related peptide,","Effectiveness,","Real-life,","Migraine,","Safety","Treatment","2025-04-29",{"date":530,"type":53},"2025-05-01",{"date":532,"type":53},"2023-01-01",{"date":534,"type":24},"2026-12-31",{"name":426,"class":60},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":378,"minAge":20,"maxAge":21,"enrollmentInfo":543,"targetDuration":4,"studyType":125,"phases":545,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":152},"100492330","tai-chi-for-the-prophylaxis-of-episodic-migraine-the-efficacy-examination-and-mechanism-exploration-100492330","NCT05690737","Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration","A Randomized Controlled Trail to Examine the Efficacy of Tai Chi for the Prophylaxis of Episodic Migraine Compared With Standard Prophylactic Medication in Chinese Women and a Pre-post Neuroimaging and Laboratory-based Study to Explore the Mechanism of Tai Chi's Intervention Effect","Inclusion Criteria:\n\n* Chinese woman, aged 18-65 years.\n* Have a clinical diagnosis of episodic migraine (migraine with less than 15 attacks per month) with or without aura according to the International Classification of Headache Disorders, 3rd edition (ICHD-3).\n* First migraine attack before the age of 45 years.\n* Between two and six migraine attacks in one month.\n* At least one of the following migraine characteristics is met: nausea, vomiting, photophobia, or phonophobia.\n* Duration of migraine attacks is 2-72 h without acute medication or at least 1 h with acute medication.\n* Able to undertake designated level of Tai Chi exercise.\n* Live in Hong Kong.\n\nExclusion Criteria:\n\n* Severe migraine attacks with disabilities that cannot perform moderate intensity physical activity.\n* Secondary headache and other neurological disease.\n* More than 5 days of non-migrainous headache per month.\n* Experience with Tai Chi or other body-mind exercises (yoga, biofeedback, medication, etc.) after diagnosis of migraine.\n* Undergoing other alternative therapeutic treatments during recruitment period, or received other alternative therapeutic treatments in the past 12 weeks.\n* Pregnancy, lactation period, or currently using contraceptives.\n* Use of pharmacological prophylactic treatment for migraine in the past 12 weeks.\n* Drug abuse, take antipsychotic or antidepressant drugs, or take analgesics for other chronic pain more than 3 days a month in the past 12 weeks.\n* Epilepsy, or have a psychiatric disease.",{"count":544,"type":24},220,[127],"The proposed study aims to examine the clinical efficacy of 24-week Tai Chi training in the prophylaxis of episodic migraine comparing with standard prophylactic medication in Hong Kong Chinese women, and to explore the mechanism of Tai Chi's intervention effect by examining the associations of changes in migraine features with neurovascular and neuroinflammation variations.",[31],[29,549,550,551,552],"Tai Chi","Women","Mechanism","Prophylaxis","2025-04-01",{"date":555,"type":53},"2025-04-03",{"date":557,"type":53},"2023-09-11",{"date":504,"type":24},{"name":560,"class":60},"The Hong Kong Polytechnic University",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":19,"minAge":568,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":125,"phases":572,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":279},"100419966","phase-4-qudexy-xr-for-the-prevention-of-migraine-in-children-6-to-11-years-old-100419966","NCT04748601","Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy(R) XR in the Prevention of Migraine in Children 6 to 11 Years of Age","Inclusion Criteria:\n\n1. Subject is a female or male 6 to 11 years of age, inclusive, at Visit 1 (Screening)\n2. Subject weighs at least 17.0 kg and less than 50.0 kg at Visit 1 (Screening) based on 95 percentile weight for the age range.11\n3. Subject has at least a 6-month history of headaches consistent with a diagnosis of migraine with or without aura (International Classification of Headache Disorders, 3rd Edition \\[ICHD 3\\]).\n4. Subject had ≥8 self-reported headache days in the 28 days prior to Screening.\n5. Subject has a PedMIDAS score \\>10, indicating at least mild disruption in daily activities, and \\\u003C140, indicating extreme disability that may require more comprehensive, multi component therapy.\n\nExclusion Criteria:\n\n1. Subject has continuous migraines, defined as an unrelenting headache for a 28-day period.\n2. Subject is currently receiving treatment or has used Botulinum toxin (Botox®) within 3 months prior to Visit 1 (Screening).\n3. Subject is currently receiving migraine prevention medication and has initiated or changed the dose within 28 days of Screening or is unwilling to avoid making a change during the duration of the study.\n4. Subject has previously failed an adequate trial of topiramate (at least 3 months duration at a clinically appropriate dose) for prophylaxis of migraine headache due to lack of efficacy or AEs.\n5. Subject has previously failed an adequate trial of \\>3 migraine preventative medications.\n6. Subject has a known history of allergic reaction to topiramate or any excipient in Qudexy XR.\n7. Subject has a diagnosis or history of disease that may interfere with safety or evaluation of the study drug.\n8. Subject is currently using an investigational drug or device or has used such within 30 days prior to Visit 1.\n9. Subject has begun menses and any of the following:\n\n   1. Subject has tested positive for pregnancy; OR\n   2. Subject is pregnant, planning pregnancy, or lactating; OR\n   3. Subject is taking an oral hormonal contraceptive (either combined \\[estrogen and progestogen containing\\] or progestogen-only) and is unable or unwilling to switch to an alternative highly effective contraceptive method.","6 Years","11 Years",{"count":571,"type":24},132,[437],"A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.",[31],"2025-01-22",{"date":577,"type":53},"2025-01-27",{"date":579,"type":53},"2021-02-19",{"date":581,"type":24},"2026-09",{"name":583,"class":82},"Upsher-Smith Laboratories",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":591,"targetDuration":4,"studyType":125,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":61},"100572630","closed-loop-rtms-for-short-term-migraine-prevention-100572630","NCT06735768","Closed-loop RTMS for Short-term Migraine Prevention","Double-blind, Randomized, Sham-controlled Study of Closed-loop Repetitive Transcranial Magnet Stimulation (rTMS) for the Short-term Prevention of Migraine","Inclusion criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18-65\n* Migraine without aura, migraine with aura or chronic migraine according to the diagnostic criteria of the third edition of the International Classification of Headache Disorders (ICHD-3) - Age of onset before 50 years of age\n* At least 4 migraine days in each of three subsequent 4- week periods preceding the screening period. (Subsequently, the investigators use month synonymous for 4-week periods)\n* At least 4 migraine days during one month of baseline prior to treatment.\n* Ability to distinguish migraine headaches from other headache types (e.g., tension-type headaches)\n* Willing to adhere to the rTMS regimen and able to monitor MD in Migraine diary\n* No changes in medication usage\u002Fregime for three months before the start of treatment (incl. use of acute abortion \u002F rescue medication). In case of Erenumab, Fremanezumab, Galcanezumab no changes in usage\u002Fregime for six months before the start of treatment. Every medication is reported and documented.\n* No changes in medication usage\u002Fregime during the entire study period (i.e., keeping acute intervention protocol as previously handled for the past three months; not introducing new approaches in intervention\u002F prevention during this time period (such as anti-nausea drugs not previously taken)). Every medication is reported \\& documented.\n* Use of a single drug for migraine prophylaxis is permitted as long as the dosage has not been altered within 3 months of starting the study and the dosage must not be altered for the entire duration of the study.\n* No other stimulation techniques.\n* No change in acupuncture, relaxation training, biofeedback, behavioral therapy or other psychological or psychotherapeutic interventions for three months preceding the study and during the entire study period investigator.\n* Ability to read and understand the written information (patient information, migraine diary, CRF and Adverse Events (AE) collecting form)\n* Completed baseline headache diary with missing data on not more than 5 of 28 days.\n\nExclusion criteria:\n\n* More than 26 headache days in any of three subsequent months preceding the screening visit.\n* More than 26 headache days during baseline\n* Pregnant persons\n* Usage of Onabotulinumtoxin A for managing chronic migraines.\n* Medication-overuse according to ICHD-3\n* Presence of metals or implanted devices that can be in close proximity the of device (i.e., above the neckline) and can be adversely affected by magnetic fields including:\n\n  * Stents\n  * Implanted stimulators\n  * Implanted vagus nerve or brain implants incl. deep brain stimulators\n  * Implanted electrical devices\n  * Cochlear implants for hearing\n  * Any magnetic implants\n  * Bullet fragments\n  * Grenade fragments\n* Presence of heart pacemakers, defibrillator, intracardiac lines or medication pumps\n* Known severe adverse reactions in response to rTMS\n* Patients diagnosed with bipolar disorder, substance use disorders or psychosis\n* Patients with a known medical history, as well as a family history, of seizures.\n* Patients experiencing chronic sleep deprivation\n* Patients with structural CNS disorders such as a brain tumor, stroke, or traumatic brain injury.\n* Patients with chronic tinnitus in the judgement of the investigator\n* Patients with other disorders interfering with the study in the judgement of the investigator.\n* Treatment with another investigational drug or other intervention until the end of the study\n* Botulinum toxin-based infusions for cosmetic reasons at the forehead within a period of six months prior to study inclusion until the final visit.\n* Other clinically relevant pain syndromes\n* Depression or anxiety in the judgement of the investigator as assessed by means of BDI-II (score 20 or above) and DASS-21 (score 14 or above).\n* Severe health risks in the judgement of the investigator. In particular this includes assessing the risk associated with a history of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.",{"count":592,"type":24},88,[127],"Migraine is a prevalent and debilitating primary headache disorder, where patients suffer from disabling symptoms that usually consist of a moderate to severe headache lasting 4 to 72 hours, nausea and\u002For vomiting, phonophobia and photophobia. Transcranial magnetic stimulation (TMS) is a noninvasive technique that is considered to be safe. Repetitive TMS (rTMS) might be useful for migraine prophylaxis. However, available studies on the use of rTMS for preventive treatment of migraine are limited. Currently, rTMS is not recommended in the recent guidelines for the treatment of migraine published by the German Neurological Society in 2022.\n\nTherefore, the aim of the current study is to provide reliable data on the short-term effect of rTMS for the prevention of migraine. The investigators will follow the Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition, with the exception of study duration, which will be limited to four weeks of baseline, three sessions of rTMS within a 10-day timeframe and 4 weeks of follow-up as our study aims to examine short-term efficacy.",[31],"2024-12-23",{"date":598,"type":53},"2024-12-27",{"date":600,"type":53},"2024-12-09",{"date":602,"type":24},"2025-08",{"name":604,"class":82},"Brightmind.AI",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":26,"phases":4,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":61},"100554804","migraine-attack-treatment-response-molecular-and-clinical-biomarkers-mambo-phase-i-100554804","NCT06503848","Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I","Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I","MAMBO","Inclusion Criteria:\n\n* Migraine with or without aura diagnosis according to ICHD-3 criteria\n* \\\u003C8 migraine days per month\n* Be able to read, write and understand instructions.\n* Have internet access and mail address\n* Signing of the informed consent\n\nExclusion Criteria:\n\n* Active preventive treatment for migraine\n* Active medication with an effect over the central nervous system\n* Serious physical or psychiatric condition\n* Cardiovascular or hepatic disease\n* Pregnant or breastfeeding women\n* Any triptan contraindication\n* Severe migraine attacks without previous response to triptans or NSAIDs","45 Years",{"count":615,"type":24},108,"The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan.\n\nParticipants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.",[31],[135,619],"triptan","2024-10-24",{"date":622,"type":53},"2024-10-28",{"date":624,"type":53},"2024-01-25",{"date":626,"type":24},"2024-12",{"name":628,"class":60},"Hospital Universitari Vall d'Hebron Research Institute",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":514,"enrollmentInfo":637,"targetDuration":639,"studyType":26,"phases":4,"briefSummary":640,"conditions":641,"keywords":642,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":61},"100558296","biochemical-profiling-of-migraine-patients-100558296","NCT06549270","Biochemical Profiling of Migraine Patients","Unraveling the Spectrum of Migraine Resistant to Treatments: Searching for Novel Biological PHEnotypes and theRApeutic Approaches (SPHERA Project)","SPHERA_WP1_1","Inclusion Criteria:\n\n* male and female patients aged 18 to 75 years\n* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria\n* for episodic migraine: 8-14 monthly migraine days in the previous 3 months\n* diagnosis of resistant migraine defined by: i) having failed at least 3 classes of migraine preventatives and ii) suffering from at least 8 debilitating monthly headache days for at least 3 consecutive months\n* patients naive to CGRP targeting treatments\n\nExclusion Criteria:\n\n* history of major psychiatric or other neurological conditions\n* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)\n* changes in ongoing preventive treatment (if any) in the previous 3 months\n* clinically significant medical conditions\n* chronic pain conditions\n* alcohol and\u002For drug abuse\n* pregnancy or lactation",{"count":638,"type":24},100,"3 Months","Aim of the study was to assess a potential dysfunction of the endocannabidiome system (eCBome) in migraine patients. Migraine patients who will undergo preventive therapy with monoclonal antibodies directed against the calcitonin gene related peptide (mAbs) will be evaluated through a deep phenotyping of peripheral neurochemical biomarkers (eCBome, neuropeptides, cytokines and kynurenine levels, and microRNAs expression).\n\nPrimary aim is to assess baseline differences among those patients who achieved a reduction of monthly migraine days \\>\u002F= 50% after three months of tretament (namely Responders) and those who did not (namely Non-responders).",[31,132,213],[135,643,644,645],"anti CGRP mABs","calcitonin gene related peptide","endocannabinoid system","2024-09-01",{"date":648,"type":53},"2024-09-05",{"date":650,"type":53},"2023-05-10",{"date":652,"type":24},"2026-05",{"name":654,"class":60},"IRCCS National Neurological Institute \"C. Mondino\" Foundation",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":634,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":514,"enrollmentInfo":662,"targetDuration":664,"studyType":26,"phases":4,"briefSummary":665,"conditions":666,"keywords":667,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":676,"leadSponsor":677,"locationsCount":61},"100559305","searching-for-novel-therapeutic-approaches-in-migraine-patients-resistant-to-treatments-100559305","NCT06562400","Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments","SPHERA_WP2","Inclusion Criteria:\n\n* male and female patients aged 18 to 75 years\n* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria\n* for episodic migraine: 8-14 monthly migraine days in the previous 3 months\n* diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months\n* patients naive to CGRP targeting treatments\n\nExclusion Criteria:\n\n* history of major psychiatric or other neurological conditions\n* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)\n* clinically significant medical conditions\n* chronic pain conditions\n* alcohol and\u002For drug abuse\n* pregnancy or lactation",{"count":663,"type":24},45,"6 Months","Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group.\n\nThey will be identified as patients showing a reduction of monthly migraine days \\\u003C 50% after three months of treatment.\n\nThe clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients",[31,132,213],[135,643,644,645,668,669,670,671],"HD EEG","functional MRI","brain connectivity","miocrobiome","2024-08-17",{"date":674,"type":53},"2024-08-20",{"date":650,"type":53},{"date":652,"type":24},{"name":654,"class":60},{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":634,"acronym":683,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":514,"enrollmentInfo":685,"targetDuration":664,"studyType":26,"phases":4,"briefSummary":686,"conditions":687,"keywords":688,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":689,"startDateStruct":690,"completionDateStruct":691,"leadSponsor":692,"locationsCount":61},"100559306","searching-for-novel-biological-phenotypes-in-migraine-patients-resistant-to-treatments-100559306","NCT06562413","Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments","SPHERA_WP1_2","Inclusion Criteria:\n\n* male and female patients aged 18 to 75 years\n* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria\n* for episodic migraine: 8-14 monthly migraine days in the previous 3 months\n* diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months\n* patients naive to CGRP targeting treatments\n\nExclusion Criteria:\n\n* history of major psychiatric or other neurological conditions\n* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)\n* changes in ongoing preventive treatment (if any) in the previous 3 months\n* clinically significant medical conditions\n* chronic pain conditions\n* alcohol and\u002For drug abuse\n* pregnancy or lactation",{"count":638,"type":24},"The investigators aim to define the neurofunctional phenotype of migraine patients who did not respond to at least 3 preventive treatments, including monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) pathway (NON-responders).\n\nPrimary aim will be to assess and compare changes in functional resting-state connectivity at baseline and after three months of mAbs treatment between patients who will achieve a reduction of monthly migraine days \\>\u002F= than 50% (namely Responders) and those who will not (namely Responders).\n\nThe 2 groups will undergo a neurofunctional profile by means of High Density-electroencephalogram (HD-EEG) and functional-magnetic resonance imaging (fMRI).",[31,132,213],[135,643,644,668,669,670],{"date":674,"type":53},{"date":650,"type":53},{"date":652,"type":24},{"name":654,"class":60}]